Introduction
The acquired immunodeficiency syndrome (AIDS), is a fatal illness caused by a retrovirus known as the human immunodeficiency virus that breaks down the body's immune system, infects CD4+ cells initially and progressively leads to AIDS. 1 There are 2.47 million persons in India living with HIV; equivalent to approximately 0.36 % of the adult population. 2 The revised national estimate reflects the availability of improved data rather than a substantial decrease in actual HIV prevalence in India. The transmission route is still predominantly sexual (87.4%); other routes of transmission by order of proportion include prenatal (4.7%), unsafe blood and blood products (1.7%), infected needles and syringes (1.8%) and unspecified routes of transmission (4.1%). 3 Men with HIV infection were reported to have hypocholesterolemia with and without hypertriglyceridemia. 4, 5 An association between plasma triglyceride and circulating interferon-levels has been observed in persons with AIDS.
However, the mechanism for hypocholesterolemia in HIV and other infections is not known. A pattern of hyperlipidemia (i.e. elevated levels of total cholesterol, lowdensity lipoprotein cholesterol, and triglycerides, and a reduced level of high-density lipoprotein cholesterol) has been observed in patients treated with protease inhibitors. 6, 7 Infection can increase plasma triglyceride levels by decreasing the clearance of circulating lipoproteins, a process considered to be the result of reduced lipoprotein lipase (LPL) or by stimulating hepatic lipid synthesis through increases in either hepatic fatty acid synthesis or reesterification of fatty acid derived from lipolysis. 8 Hypertriglyceridaemia was the first dyslipidaemia to be reported in HIV infected patients, but other lipid abnormalities such as hypocholesterolaemia or hypo HDL cholesterolaemia have also been reported. of cellular functions, characterized by a gradual decline in peripheral blood CD 4+ lymphocyte levels which results in an increasing susceptibility to a wide variety of opportunistic, viral, bacterial, protozoal, and fungal infections and to certain malignancies also. 7 Thus HIV can make copies of its own genome as DNA in the host's cells such as human T4-helper lymphocytes and this leads to the elaboration of vast numbers of viral particles. Although immunological dysfunction is common to all AIDS patients, the clinical spectrum of HIV infection is diverse and multiple organ involvement is frequently evident.
Increasing experience with this syndrome has led to the recognition of a variety of HIV related endocrine disorder that occurs during both the early and late stages of the disease. Among these disorders a high prevalence of abnormalities in thyroid function tests is reported in previous cross-sectional studies. Unique abnormalities of thyroid function tests were reported by Lambert et al. 9 They described a progressive elevation in serum thyroxin binding globulin (sr.TBG) but not in other binding proteins such as cortisol binding globulin (CBG) that accompanies a decline in CD4+ count with advancing HIV infection. FeldtRasmussen et al. reported elevation of sr. TSH and s. TBG concentration in conjunction with low FT-4 that occurs frequently and correlates with CD4+ cell depletion in AIDS patients. 10 In addition, this thyroid dysfunction correlated with the degree of immunosuppression and viral replication and preceded the worsening of the disease. Subtle alterations in thyroid function tests (TFT) are more common in HIV infection and are sometimes already detectable in the early phase of disease. The changes in thyroid function tests are HIV specific and are consistent with an abnormal response to acute illness. Various mechanisms have been proposed to explain such abnormalities in TFT. 11 These include direct infection of thyroid gland by opportunistic organisms such as Pneumocystis carinii, infiltration of the gland by tumors such as Kaposi sarcoma, effect of humoral factors such as IL-1α and TNF-α, side effect of the drugs used in the course of HIV infection for e.g. rifampicin, ketoconazole, steroids etc. and direct infection of gland by HIV. Thus we studied a spectrum of newly diagnosed HIV+ patients from asymptomatic to AIDS who were not receiving HAART. The present study was undertaken to examine the changes in lipid, CD4+ T cell counts and thyroid hormone changes in HIV infection, AIDS patients and HIV-negative controls.
investigate lipids and thyroid hormones [total T3, T4, FT3, FT4 and TSH] status among HIV infected patients 50 cases (n=50), AIDS patients 50 cases (n=50) and an equal numbers of age-and sex-matched control subjects (n=50) were investigated. The prospective study was carried out at the Sri Sugam Hospital and Sai Bhrenthavan Homeo Clinic, Salem, Tamil Nadu, India from January 2008 to January 2010. For diagnosis and confirmation of HIV infection, we followed the National AIDS Control Or ganization (NACO) recommendations for HIV testing NACO. 4 All the patients were subjected to detailed history taking and clinical examination. Informed consent of the patients was taken before testing. Individuals were classified according to the Centers for Disease Control and Prevention Criteria (CDC) classification system that emphasizes the importance of CD4 + T lymphocyte testing in clinical management of HIV-infected persons. The system is based on three ranges of CD4 counts (1) >500 mm -3 ; (2) 200-499 mm -3 ; and (3) <200 mm -3 . 12 Classification of the values into raised, low or normal thyroid hormone levels were based on the following criteria. Subjects classified as having raised level of thyroid hormones: had FT4 values > 1.6ng/l or, TSH < 0.4miu/ or both, those classified as having low level had FT4 values < 0.68ng/ml, or TSH values > 5.0miu/ml, or both. Subjects grouped as normal had FT4 and TSH values within the range > 0.68 -1.6ng/ml, and 0. 4 -5.0miu/ml respectively.
Sample collection
Single sample of 10-ml. ante-cubical venous bloods was obtained with all aseptic measure. After let to clot, the blood was centrifuged for 30 minutes and the supernatant (serum) was taken in a separate test tube. Thus the serum was ready and used for hormone analysis in the laboratory.
Biochemical investigation
The levels of serum thyroid stimulating hormone (TSH), total triiodothyroxine (T3), free thyroxine (FT4) and free triiodothyronine (FT3) were measured by a Microparticle Enzyme Immunoassay (MEIA) on AXSYM System (Abbott Laboratories, Abbott Park, USA) while serum total thyroxine (T4) was measured by the Fluorescence Polarization Immunoassay (FPIA) method on AXSYM System using the standard laboratory methodologies. Serum lipids were determined using fully automated clinical chemistry analyzer (Hitachi 912, Boehringer Mannheim, Germany). Red blood cell count, total white blood cell count, platelet count, total hemoglobin, hematocrit and ESR were determined using fully automated hematology analyzer (Pentra-XL80, Horiba ABX, USA). The CD 4+ lymphocyte count was estimated by Fluorescence Activated Cell Sorter (FACS) count system (Becton Dickinson, USA).
Materials and Methods

Study Population
The population consisting of 150 subjects divided into three groups was selected. The objective of this study was to 132 Statistical analysis All data were expressed as mean ± SD. The statistical significance was evaluated by Student's t test and the MannWhitney U-test was used. Statistical analyses were performed with Statistical Package for Social Sciences software (SPSS Cary, NC, USA) version 10.0. A p value of less than <0.05 was considered statistically significant. and ESR were significantly increased in HIV infected and AIDS patients. The above-mentioned hematological parameters were found to be more significantly altered in AIDS patients compared with HIV infected subjects. Table III shows the lipids level changes in HIV infected patients, AIDS patients and normal healthy subjects. The levels of total cholesterol, HDL and LDL were significantly decreased, while the level of triglyceride and VLDL were significantly increased in AIDS patients when compared to HIV infected patients and normal subjects, but the levels of VLDL in the HIV infected patients and control subjects did not differ significantly. Table IV showing the level of thyroid hormone (TT3, TT4, FT3, FT 4 and TSH) changes in normal healthy subjects, HIV infection and AIDS patients. There were no significant differences in total TT4 concentrations among the AIDS patients when compared to HIV infection and normal healthy subjects. A measured FT4 concentration was significantly decreased in HIV infected and AIDS patients. Total T3 concentrations were normal in HIV infected patients, but decreased in AIDS; more important, T3 level was decreased in AIDS patients. The level of FT3 concentration was significantly increased in HIV infected and significantly decreased in AIDS patients. As all TSH levels were within the normal range; however, there was a small but significantly increase in TSH levels in AIDS, and there was a trend toward an increase in TSH levels in AIDS compared with controls. Table I . The mean age limit was 49 ± 13.4 inAIDS patients, 47 ± 10.2 in HIV infected patients and 48 ± 9.3in control subjects. The decrease in body mass index in AIDS patients (22.5 ± 6.9kg/m 2 ) compared with HIV infected patients (30.8 ± 7.1 kg/m 2 ) and control subjects (32.7 ± 6.7kg/m 2 ) were statistically significant. On the other hand the drastically decreased body mass index in AIDS patients compare with HIV infection was highly significant. The increased number of hypertension, smokers and alcoholics were observed in AIDS patients compared with HIV infection and control subjects. Table II shows the levels of CD 4+ cell count, total RBC count, WBC count, platelet count, hemoglobin, hematocrit and ESR in control, HIV infected and AIDS patients. The levels of CD 4+ cell count, total RBC count, platelet, hemoglobin and hematocrit were significantly decreased in AIDS patients when compared with HIV infected patients and control subjects. On the other hand, the level of total WBC count Table- Values are given as mean ± S.D from fifty subjects in each group *AIDS patients compared with control subjects † HIV infection compare with control subjects ‡ AIDS patients compare with HIV infection NS-Not significant; p<0.05 considered statistically significant
Results
Information about the investigated characteristics is shown in
Table-III Changes in the level of total cholesterol, triglyceride, HDL, LDL and VLDL in control, HIV infection and AIDS patients
Discussion
The present study showed that lipid profile was altered in HIV infected and AIDS patients. Alteration in the lipid profile occurred even during the early stages of HIV infection and, more so, as the disease progressed. This high number of AIDS cases and the fact that there were no patients in clinical stage in our study could be due to the fact that patients with HIV infection seek hospital admission only in the late clinical stages when they have opportunistic infections. 4
Previous studies have demonstrated that patients with AIDS exhibit highly abnormal total lipid concentrations in plasma. 13 A few authors have determined the levels of plasma triglycerides, total cholesterol and HDL cholesterol in HIV infected individuals by the level of immunological deficiency according to the CD4+ cell count, also came to the same conclusion that, with an increase of immunological deficiency and clinical development of HIV infection, lipid profile disorders, indicated by an increase in triglyceride level and decreased concentrations of HDL cholesterol intensified as well. 14 Consistent with earlier reports, our study also showed similar findings in which the decrease of CD4+ count due to disease progression was accompanied by decrease in total cholesterol, HDL and LDL, and increase in triglyceride and VLDL levels.
Our findings are also consistent with reports from Ducobu and Payen, who stated that HIV infection induced an early decrease of cholesterol and a late increase of triglyceride with a reduction of HDL. 14 These changes were proportional During HIV infection abnormalities in thyroid include both pathological changes and disturbances in its function. 11, 19 Our present study shows that thyroid dysfunction is frequent in HIV infection and with progression of disease there is a subclinical hypothyroid like stage that occurs in patients with advancing HIV infection. 20 Various thyroid function tests such as FT3 /FT4 /serum TSH can be used as a surrogate marker as these correlate with the progression of the disease. One should not start upon the replacement therapy for hypothyroid like state in HIV infection, as the state may be responsive to highly active antiretroviral therapy. Our present study may give the true picture of thyroid abnormality in HIV-AIDS patients. To conclude, abnormal TFTs are encountered often in HIV infection and AIDS patient's individuals. Management guidelines exist for overt dysfunction as described above. However, larger studies are needed to evaluate the prevalence and outcomes of mild thyroid dysfunction in HIV-infected patients and to formulate screening and treatment guidelines.
